Yue Yu

3.0k total citations
139 papers, 2.1k citations indexed

About

Yue Yu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Yue Yu has authored 139 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Molecular Biology, 52 papers in Cancer Research and 34 papers in Oncology. Recurrent topics in Yue Yu's work include RNA modifications and cancer (23 papers), Cancer-related molecular mechanisms research (19 papers) and Epigenetics and DNA Methylation (15 papers). Yue Yu is often cited by papers focused on RNA modifications and cancer (23 papers), Cancer-related molecular mechanisms research (19 papers) and Epigenetics and DNA Methylation (15 papers). Yue Yu collaborates with scholars based in China, United States and South Korea. Yue Yu's co-authors include Xuchen Cao, Yu‐Mei Feng, Jie Ge, Xu-Chen Cao, Bin Zhang, Xin‐Xiang Zhang, Xin Wang, Di Zhang, Ying‐Lin Zhou and Xiaohui Zhang and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yue Yu

125 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yue Yu China 25 1.3k 707 340 222 174 139 2.1k
Xiangling Feng China 24 1.1k 0.9× 503 0.7× 269 0.8× 101 0.5× 98 0.6× 80 1.9k
Fan Yao China 27 1.7k 1.3× 1.1k 1.5× 570 1.7× 221 1.0× 183 1.1× 99 2.8k
Jie Ning China 23 1.0k 0.8× 397 0.6× 135 0.4× 147 0.7× 106 0.6× 91 1.6k
Haishan Huang China 28 1.4k 1.0× 654 0.9× 259 0.8× 131 0.6× 112 0.6× 78 1.9k
Daniela Mennerich Finland 16 1.0k 0.8× 469 0.7× 158 0.5× 93 0.4× 125 0.7× 24 1.9k
Bo Pang China 26 1.2k 0.9× 409 0.6× 170 0.5× 165 0.7× 65 0.4× 96 2.1k
Xia Liu China 20 1.6k 1.2× 745 1.1× 242 0.7× 420 1.9× 77 0.4× 72 2.5k
Chunyan Li China 22 1.1k 0.8× 487 0.7× 266 0.8× 202 0.9× 71 0.4× 90 1.9k

Countries citing papers authored by Yue Yu

Since Specialization
Citations

This map shows the geographic impact of Yue Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yue Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yue Yu more than expected).

Fields of papers citing papers by Yue Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yue Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yue Yu. The network helps show where Yue Yu may publish in the future.

Co-authorship network of co-authors of Yue Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Yue Yu. A scholar is included among the top collaborators of Yue Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yue Yu. Yue Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Junping, Junming Cao, Rui Sun, et al.. (2025). SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression. Breast Cancer Research. 27(1). 20–20. 1 indexed citations
2.
Wang, Guixin, Shuo Wang, Wenbin Song, et al.. (2025). Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer. BMC Cancer. 25(1). 623–623. 4 indexed citations
3.
4.
Guo, Zhao, Yuning Wang, Shujun Xing, et al.. (2024). Exosome-based anticancer vaccines: From Bench to bedside. Cancer Letters. 595. 216989–216989. 22 indexed citations
5.
Wu, Tianyu, Yue Yu, Yan Hua, et al.. (2024). Long noncoding RNA AK144717 exacerbates pathological cardiac hypertrophy through modulating the cellular distribution of HMGB1 and subsequent DNA damage response. Cellular and Molecular Life Sciences. 81(1). 432–432. 1 indexed citations
6.
Li, Dan, Qian Li, Bin Zhang, et al.. (2024). Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. The Oncologist. 29(6). e763–e770. 5 indexed citations
7.
8.
Huang, Wenwen, Lixuan Chen, Jie Min, et al.. (2023). Clinicopathological characteristics, local treatment, and prognostic factors in IE/IIE primary breast lymphoma: a retrospective study of 67 patients. World Journal of Surgical Oncology. 21(1). 127–127. 1 indexed citations
9.
Tian, Tian, et al.. (2023). Primary Angiosarcoma of the Breast: A 20-Year Single-Institution Experience in China. European Journal of Cancer Care. 2023. 1–9.
10.
Tian, Yao, Zhaohui Chen, Di Zhang, et al.. (2023). MIR497HG‐Derived miR‐195 and miR‐497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer. Advanced Science. 10(12). e2204819–e2204819. 50 indexed citations
11.
Yu, Yue, et al.. (2023). HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. Breast Cancer. 30(3). 364–378. 13 indexed citations
12.
Yang, Zhengjun, et al.. (2022). The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score. Cancer Medicine. 12(3). 2493–2504. 14 indexed citations
13.
Zhang, Ai, Rui Wang, Qianfeng Liu, et al.. (2022). Breast adipose metabolites mediates the association of tetrabromobisphenol a with breast cancer: A case-control study in Chinese population. Environmental Pollution. 316. 120701–120701. 6 indexed citations
14.
Li, Xuejun, Fengju Song, Xiaotu Liu, et al.. (2022). Perfluoroalkyl substances (PFASs) as risk factors for breast cancer: a case–control study in Chinese population. Environmental Health. 21(1). 83–83. 24 indexed citations
15.
Yu, Yue, et al.. (2021). EZH2‐mediated SLC7A11 upregulation via miR‐125b‐5p represses ferroptosis of TSCC. Oral Diseases. 29(3). 880–891. 35 indexed citations
16.
Liu, Xue‐Qi, Ye Liu, Zhaoxia Dong, et al.. (2021). Tight junction protein 1 promotes vasculature remodeling via regulating USP2/TWIST1 in bladder cancer. Oncogene. 41(4). 502–514. 15 indexed citations
17.
18.
Cheng, Jie, Yan Huang, Xiaohui Zhang, et al.. (2020). TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. Nature Communications. 11(1). 1880–1880. 98 indexed citations
19.
Jiao, Jie, Wenhui Zhou, Huanling Zhang, et al.. (2018). Effect of GRM7 polymorphisms on the development of noise-induced hearing loss in Chinese Han workers: a nested case-control study. BMC Medical Genetics. 19(1). 4–4. 21 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiangling Feng Breakdown of academic impact, for papers by Fan Yao Breakdown of academic impact, for papers by Jie Ning Breakdown of academic impact, for papers by Haishan Huang Breakdown of academic impact, for papers by Daniela Mennerich Breakdown of academic impact, for papers by Bo Pang Breakdown of academic impact, for papers by Xia Liu Breakdown of academic impact, for papers by Chunyan Li
Rankless by CCL
2026